Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
Eur J Cell Biol ; 90(4): 333-41, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21122942

ABSTRACT

Glycine receptor (GlyR) activation by glycine protects cells against ATP depletion. However, the underlying mechanisms remain unclear. To define signaling pathways responsible for the GlyR mediated cytoprotection, we examined the phosphorylation status of key kinases signaling pathways in Madin-Darby canine kidney (MDCK) cells. Our results indicated that growing the ATP-depleted MDCK cells in glycine-containing media increased the level of phosphorylated extracellular signal-regulated kinase 1 and 2 (ERK1/2), Ets-like transcription factor-1 (Elk1), AKT, and Forkhead box O-class 1 (FoxO1), decreased the level of phosphorylated p38 mitogen-activated protein kinase, while having little effect on the phosphorylation status of c-Jun N-terminal kinase 1 and 2. Similar phosphorylation changes in these molecules took place in the GlyRα1 stably expressing HEK-293 cell. We also showed that treating MDCK cells with ERK1/2 inhibitor PD98059 or AKT inhibitor LY294002 diminished cytoprotection against cell death by glycine, as determined by assessment of lactate dehydrogenase release and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide activity. In contrast, treatment with p38 inhibitor SB203580 enhanced the glycine-induced cytoprotection. Finally, RNAi-mediated silencing of GlyRα1 abolished the glycine-induced changes in phosphorylation status of the above kinases in ATP-depleted cells. Taken together, our results suggest that the ERK1/2 and AKT signaling pathways are involved in the glycine-GlyR protection of MDCK cells against death induced by ATP depletion.


Subject(s)
Adenosine Triphosphate/metabolism , Glycine/pharmacology , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 3/genetics , Proto-Oncogene Proteins c-akt/metabolism , Receptors, Glycine/metabolism , Animals , Cell Death , Cytoprotection , Dogs , HEK293 Cells , Humans , Imidazoles/pharmacology , Kidney/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Phosphorylation , Proto-Oncogene Proteins c-akt/genetics , Pyridines/pharmacology , Receptors, Glycine/agonists , Receptors, Glycine/genetics , Signal Transduction/genetics , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/genetics
2.
Neurosci Lett ; 460(2): 133-7, 2009 Aug 28.
Article in English | MEDLINE | ID: mdl-19477222

ABSTRACT

In our previous studies, Tat-GluR6-9c (a glutamate receptor 6 C-terminus peptide fused the TAT protein transduction sequence) not only inhibited the activation of MLK3 (mixed lineage kinase 3) and JNK (c-Jun N-terminal kinase) via the GluR6.PSD-95 (postsynaptic density protein 95).MLK3 signaling module but also diminished neuronal death induced by kainic acid or transient cerebral ischemia in rat hippocampus. Here, we investigate whether overexpression of the PDZ1 domain of PSD-95 protein could suppress the binding of GluR6 with PSD-95 and the activation of MLK3, MKK7 (mitogen-activated kinase kinase 7) and JNK1/2, and rescused neuronal cell death induced by kainic acid. Our results showed that overexpression of the PDZ1 domain of PSD-95 protein could prevent nuclear accumulation and abrogate neuronal cell death in SD (Sprague-Dawley) rat hippocampal neuronal cells. Further studies indicated that overexpression of PDZ1 could inhibit the enhancement of binding of GluR6 to PSD-95 and prevent the activation of MLK3, MKK7 and JNK1/2 induced by kainic acid. Taken together, the essential role of the PDZ1 domain of PSD-95 in apoptotic cell death in neurons provides an experimental foundation for gene therapy of neurodegenerative diseases with overexpression of the PDZ1 domain.


Subject(s)
Apoptosis/drug effects , Excitatory Amino Acid Agonists/pharmacology , Hippocampus/cytology , Kainic Acid/pharmacology , Neurons/drug effects , PDZ Domains/physiology , Animals , Animals, Newborn , Apoptosis/genetics , Cells, Cultured , Gene Expression Regulation/drug effects , Green Fluorescent Proteins/genetics , Humans , MAP Kinase Kinase 7/metabolism , MAP Kinase Kinase Kinases/metabolism , Mitogen-Activated Protein Kinase 8/metabolism , PDZ Domains/genetics , Rats , Rats, Sprague-Dawley , Receptors, Metabotropic Glutamate/metabolism , Signal Transduction/physiology , Time Factors , Transfection/methods , Mitogen-Activated Protein Kinase Kinase Kinase 11
3.
Exp Physiol ; 94(7): 785-94, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19346334

ABSTRACT

Sympathetic outflow is increased in hypertension. The aim of the present study was to investigate whether the cardiac sympathetic afferent reflex (CSAR) is enhanced in two-kidney one-clip (2K1C) renovascular hypertensive rats, and whether the enhanced CSAR contributes, in part, to the increased sympathetic outflow. Furthermore, the role of central angiotensin II type 1 (AT(1)) receptors in mediating the CSAR was determined. Under urethane and alpha-chloralose anaesthesia, the renal sympathetic nerve activity (RSNA) and mean arterial pressure (MAP) were recorded in sinoaortic denervated and cervical vagotomized rats. The CSAR was evaluated by the response of RSNA and MAP to epicardial application of 1.0 nmol of capsaicin. Compared with sham-operated rats, the CSAR, baseline RSNA and plasma noradrenaline level were significantly enhanced in 2K1C rats. Intrapericardial administration of resiniferatoxin, which abolishes the CSAR because of the desensitization of transient receptor potential vanilloid 1-containing cardiac afferent fibres, decreased the RSNA and MAP. The enhanced CSAR in 2K1C rats was normalized by intracerebroventricular administration of the AT(1) receptor antagonist losartan. Intracerebroventricular administration of angiotensin II further potentiated the enhanced CSAR in 2K1C rats, a response which was abolished by pretreatment with losartan. These results indicate that the CSAR is enhanced in 2K1C rats and the enhanced CSAR contributes, in part, to the sympathetic activation and hypertension. Central AT(1) receptors are involved in the enhanced CSAR in 2K1C rats.


Subject(s)
Reflex/physiology , Sympathetic Nervous System/physiopathology , Angiotensin II/physiology , Animals , Aortic Coarctation/physiopathology , Hypertension, Renovascular/physiopathology , Injections, Intravenous , Injections, Intraventricular , Losartan/administration & dosage , Losartan/pharmacology , Male , Rats , Rats, Sprague-Dawley , Receptor, Angiotensin, Type 1/physiology , Reflex/drug effects
4.
Biochim Biophys Acta ; 1791(1): 76-83, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19049904

ABSTRACT

Class A scavenger receptor (SR-A) contributes primarily to lipid accumulation in cells. The cytoplasmic domain of SR-A (CSR-A) is responsible for internalization of the receptor-ligand complex into cells. In the present study we tried to reduce cellular uptake of acetylated low density lipoprotein (AcLDL) by inducing the interaction between the CSR-A and a novel peptide H11, which was screened from a phage-displayed peptide library. When H11 was fused with a cross membrane peptide TAT, the fusion peptide could enter cell efficiently. The peptide H11 inhibited the binding and uptake of DiI-AcLDL and attenuated lipid accumulation in the differentiated human acute monocytic leukemia cell line (THP-1) macrophages. Furthermore, the interaction of peptide H11 with the CSR-A inhibited the expression of SR-A protein as well as the phosphorylation of c-jun N-terminal kinase 2 (JNK2) in cells, which mediates cellular lipid accumulation-related signaling pathways. These results suggest that the CSR-A can be a potential target to prevent lipid accumulation in cells. The peptide H11 may be useful in regulating SR-A functions in macrophages.


Subject(s)
Lipid Metabolism/drug effects , Macrophages/metabolism , Peptides/pharmacology , Scavenger Receptors, Class A/metabolism , Cell Line , Humans , Macrophages/drug effects , Mitogen-Activated Protein Kinase 9/antagonists & inhibitors , Peptide Library , Peptides/metabolism , Recombinant Fusion Proteins/pharmacology , Signal Transduction/drug effects
5.
Mol Med Rep ; 2(6): 931-6, 2009.
Article in English | MEDLINE | ID: mdl-21475923

ABSTRACT

This study was designed to investigate the repair of point mutations in the low density lipoprotein receptor (LDLR) gene mediated by single-stranded oligonucleotides (SSOs) in vivo. Mutations in the LDLR gene are known to be the prime cause of familial hypercholesterolemia (FH). SSOs result in sequence-specific alterations leading to the correction of mutations. In the present study, the LDLR gene with a nonsense mutation (c660x) was fused to a luciferase reporter gene (p660-LDLR-luc) and introduced into mouse liver by hydrodynamic gene transfer. These mice were then injected via the tail vein with different SSOs complexed with polyethylenimine. Firefly luciferase activity present in hepatic cell lysate was measured to analyze repair efficiency. Restriction fragment length polymorphism analysis and direct sequencing were performed to affirm that the LDLR mutation was corrected. The results indicate that the LDLR mutation was corrected in the liver in vivo only in the presence of antisense SSOs (anti-SSOs). Our findings provide initial evidence that the point mutation in p660-LDLR-luc can be corrected by anti-SSO targeted repair in vivo. This may be a potential strategy for the treatment of FH.

6.
Clin Exp Pharmacol Physiol ; 35(10): 1172-7, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18565194

ABSTRACT

Peroxisome proliferrator-activated receptor gamma coactivator-1alpha (PGC-1alpha; PPARGC1A) is a coactivator of the nuclear hormone receptor family that participates in the transcriptional programme of lipid metabolism and oxidative stress implicated in atherogenesis. Therefore, in the present study, we investigated PPARGC1A polymorphisms in the prevalence of coronary artery disease (CAD). A case-control study comprising 342 patients with CAD and 334 controls was performed in a Chinese population. Two single nucleotide polymorphisms (Gly482Ser and Thr394Thr) in the PPARGC1A gene were genotyped and compared using the polymerase chain reaction-restriction fragment length polymorphism method. The XA (GA + AA) genotype of Gly482Ser displayed a higher frequency in CAD patients than that in control subjects (P = 0.019; adjusted odds ratio = 1.53; 95% confidence interval 1.06-2.20). No significant difference in Thr394Thr genotype distribution or in Gly482Ser-Thr394Thr haplotype combinations was found between CAD patients and controls. Furthermore, we found that the significantly increased risk of CAD associated with the XA genotypes of Gly482Ser was more evident among subjects who were younger than 64 years of age, female, overweight and with hypertension. The results indicate that the PPARGC1A Gly482Ser polymorphism may contribute to the risk of CAD in the Chinese population investigated.


Subject(s)
Asian People/genetics , Coronary Artery Disease/genetics , Heat-Shock Proteins/genetics , Polymorphism, Single Nucleotide/genetics , Transcription Factors/genetics , Case-Control Studies , Coronary Artery Disease/diagnosis , Female , Genetic Markers/genetics , Genotype , Haplotypes/genetics , Humans , Male , Metabolic Syndrome/diagnosis , Metabolic Syndrome/genetics , Middle Aged , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , Risk Factors
7.
Life Sci ; 82(25-26): 1249-55, 2008 Jun 20.
Article in English | MEDLINE | ID: mdl-18505701

ABSTRACT

Beta-amyloid (Abeta) has been suggested as a potent neurotoxic agent. The Abeta-targeted immunotherapy aims to clear diffuse amyloid deposits and reverse memory deficits in Alzheimer's disease. We generated a human single chain variable domain antibody fragment (scFv) against Abeta40, termed E3, by screening a phage antibody library. E3 scFv could recognize Abeta in human cerebral cortex. It was able not only to prevent the aggregation of Abeta but also to disrupt the Abeta preexisting fibrils. Moreover, the Abeta toxicity to SK-N-SH cells was attenuated by addition of E3 scFv. Our results indicate that site-directed human scFv might be a potential therapeutic agent for Alzheimer's disease.


Subject(s)
Amyloid beta-Peptides/metabolism , Amyloid beta-Peptides/toxicity , Immunoglobulin Variable Region/metabolism , Aged , Amyloid beta-Peptides/chemistry , Amyloid beta-Peptides/ultrastructure , Antibodies/isolation & purification , Bacteriophages , Blotting, Western , Cell Death/drug effects , Cell Line, Tumor , Cerebral Cortex/pathology , Humans , Immunoglobulin Variable Region/isolation & purification , Immunoglobulin Variable Region/ultrastructure , Immunohistochemistry , Protein Binding/drug effects , Protein Structure, Quaternary
8.
Clin Exp Pharmacol Physiol ; 35(5-6): 546-51, 2008 May.
Article in English | MEDLINE | ID: mdl-17973931

ABSTRACT

1. High-density lipoprotein (HDL) is widely accepted as a lipoprotein that protects against coronary artery and other atherosclerotic diseases. Recently, a new apolipoprotein encoded by the APOM gene, which plays an important role in affecting the intrinsic properties of HDL, has been reported. Genetic variations exist in the APOM gene, but their significance is presently unclear. The aim of the present study was to elucidate whether the APOM T-855C mutant allele is implicated in coronary artery disease (CAD). 2. In the present study, 418 patients with CAD and 372 controls were studied, all of whom were Han Chinese from Jiangsu Province, China. Plasma levels of triglycerides (TG), total cholesterol (TC), HDL-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C) were evaluated. Genomic DNA from the whole blood from these subjects was subjected to polymerase chain reaction amplification and restriction enzyme digestion to determine genotype with respect to the APOM T-855C polymorphism. 3. The allelic frequencies were in Hardy-Weinberg equilibrium. Plasma HDL levels were significantly lower in subjects with CAD than in control subjects (1.08 +/- 0.31 vs 1.25 +/- 0.32, respectively; P < 0.001) and the distribution of genotypes and allelic frequencies was significantly different in the two groups (P = 0.013 and 0.005, respectively). Multiple logistic regression analysis after adjustment for age, gender, smoking, body mass index, hypertension and serum glucose showed that, compared with the wild-type TT genotype, carriers of the C allele had an increased risk of CAD (odds ratio = 1.819, 95% confidence interval 1.142-2.898; P = 0.012). 4. In conclusion, the results of the present study suggest that the APOM T-855C polymorphism carries an increased risk for CAD in this Chinese population.


Subject(s)
Apolipoproteins/genetics , Asian People/genetics , Coronary Disease/genetics , Genetic Predisposition to Disease/genetics , Genetic Variation , Aged , Alleles , Apolipoproteins M , Case-Control Studies , Female , Genotype , Humans , Lipocalins , Male , Middle Aged , Risk Factors
9.
Clin Exp Pharmacol Physiol ; 34(10): 972-8, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17714081

ABSTRACT

1. Diabetes mellitus predisposes to and female sex protects against arterial thrombosis. The aim of the present study was to determine whether advanced glycation end-products (AGE), which accumulate in diabetes, impair platelet function through effects on platelet nitric oxide (NO) generation and whether this can be prevented by 17beta-oestradiol. 2. Aggregation responses of human platelet-rich plasma to ADP were determined in the absence or presence of 200 mg/L AGE-modified albumin (AGE-albumin), 10(-5) mol/L 17beta-oestradiol and 10(-5) mol/L ICI 182 780 (the pure oestrogen receptor antagonist). 3. Intraplatelet cGMP, an index of bioactive NO, was measured by radioimmunoassay and expression of nitric oxide synthase (NOS)-3, phosphoserine-1177-NOS-3 and O-glycosylated NOS-3 was quantified by western blotting in response to these same treatments. 4. Advanced glycation end-products-albumin increased platelet aggregatory responses to ADP. This increase was largely prevented by 17beta-oestradiol. Advanced glycation end-products-albumin decreased and 17beta-oestradiol increased intraplatelet NO-attributable cGMP and 17beta-oestradiol attenuated the AGE-albumin-induced decrease in NO-attributable cGMP. Despite no effect on NOS-3 expression, AGE-albumin decreased and 17beta-oestradiol increased phosphoserine-1177-NOS-3 and 17beta-oestradiol largely prevented the decrease in phosphoserine-1177-NOS-3 induced by AGE-albumin. Alone, AGE-albumin increased O-glycosylation of NOS-3 by N-acetylglucosamine, an effect largely inhibited by 17beta-oestradiol. 5. In conclusion, AGE-albumin inhibits platelet NO biosynthesis through effects on serine phosphorylation and O-glycosylation of platelet NOS-3 and this may explain, at least in part, the increase in platelet aggregability induced by AGE-albumin. These effects of AGE-albumin are largely prevented by 17beta-oestradiol. These actions may contribute to the effects of diabetes and sex on arterial thrombosis in vivo.


Subject(s)
Blood Platelets/enzymology , Enzyme Inhibitors/pharmacology , Estradiol/pharmacology , Glycation End Products, Advanced/antagonists & inhibitors , Glycation End Products, Advanced/pharmacology , Nitric Oxide Synthase Type III/antagonists & inhibitors , Acetylglucosamine/blood , Adult , Blood Platelets/drug effects , Blotting, Western , Cyclic GMP/blood , Data Interpretation, Statistical , Electrophoresis, Polyacrylamide Gel , Estradiol/analogs & derivatives , Estrogen Antagonists/pharmacology , Female , Fulvestrant , Humans , In Vitro Techniques , Nitric Oxide Synthase Type III/isolation & purification , Phosphorylation , Phosphoserine/metabolism , Platelet Aggregation/drug effects
10.
Clin Rheumatol ; 26(12): 2073-2079, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17447103

ABSTRACT

Defects of hematopoietic stem cells (HSCs) have been suggested to contribute to the development of systemic lupus erythematosus (SLE). The aim of this study was to investigate the phenotypic characteristics of bone marrow (BM) CD34(+) cells in patients with SLE and its relationship with SLE disease activity. Ten SLE patients and 10 healthy subjects were recruited and their BM CD34(+) cells were analyzed by flow cytometric analysis with CD45/SSC gating for the expression of CD90, CD95, CD117, CD123, CD164, CD166, FAS-L, and HLA-DR. The percentage of BM CD34(+) cells was significantly decreased in active SLE patients (1.48 +/- 0.41%, n = 7) compared to the healthy controls (2.31 +/- 0.75%, n = 10, p < 0.01), but no significant difference was found between the inactive patients (2.04 +/- 0.44%, n = 3) and the controls. The expression of CD95, CD123, and CD166 on BM CD34(+) cells were significantly increased in SLE patients (48.31 +/- 10.59%, 44.9 +/- 21.5%, 30.9 +/- 19.54%, respectively, n = 10) when compared with the control subjects (24.33 +/- 11.1%, 19.5 +/- 4.4%, 10.7 +/- 5.5%, respectively, n = 10, p < 0.05). The increased CD123 expression was negatively correlated with the number of peripheral white blood cells (r = -0.700, p < 0.05, n = 10). The percentage of CD166 expression was found significantly correlated with the index of SLE disease activity (r = 0.472, p < 0.05, n = 10) and 24 h proteinuria (r = 0.558, p < 0.05, n = 10), but negatively correlated with serum C3 level (r = -0.712, p < 0.01, n = 10). Our study found that the surface marker expression of CD95, CD123, and CD166 on BM CD34(+) cells were significantly increased in patients. This supports the hypothesis that there are abnormalities of the HSC in SLE. Since CD166 and CD123 correlated with the overall lupus activity, their role as a biomarker of inflammatory disease activity also requires further study.


Subject(s)
Antigens, CD34/biosynthesis , Bone Marrow Cells/metabolism , Lupus Erythematosus, Systemic/metabolism , Adolescent , Adult , Antigens, CD/biosynthesis , Bone Marrow Cells/immunology , Cell Adhesion , Cell Adhesion Molecules, Neuronal/biosynthesis , Disease Progression , Female , Fetal Proteins/biosynthesis , Flow Cytometry , Humans , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/pathology , Male , Phenotype , Severity of Illness Index
11.
Arterioscler Thromb Vasc Biol ; 26(6): 1317-22, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16574888

ABSTRACT

OBJECTIVE: The di-leucine motif exists in the intracellular domains of certain cell surface receptors, participating in the receptor-mediated endocytosis. The present study was aimed at determining the role of the di-leucine motif in class A scavenger receptor (SR-A)-mediated ligand endocytosis. METHODS AND RESULTS: cDNA coding for a mutant (SR-A mutant N3132LM) with deletion of the di-leucine structure was transfected into Chinese hamster ovary (CHO) cells. Compared with wild-type SR-A-expressing cells, the cells expressing the SR-A mutant N3132LM showed a significant decrease in uptake but almost no change in binding of the SR-A ligand acetylated low-density lipoprotein (AcLDL). Western blot analysis revealed coimmunoprecipitation of SR-A mutant and clathrin from the lysates of the mutant but not wild-type CHO cells, suggesting that AcLDL-bound SR-A mutant N3132LM is associated with the clathrin-coated pit of cellular membrane. Removal of the first 27 amino acid residues from the SR-A N-terminus further reduced AcLDL uptake by the cells with the di-leucine motif mutation. CONCLUSIONS: The di-leucine motif of SR-A intracellular domain contributes to the SR-A-mediated cellular internalization of AcLDL. Di-leucine pair exists in the cytoplasmic domain of class A scavenger receptor. The cells expressing di-leucine mutants showed decreased uptake and unchanged binding of AcLDL. The di-leucine pair was not associated to coated pits. It suggests that di-leucine motif acts as a signal sequence to mediate SR-A into cell.


Subject(s)
Endocytosis , Lipoproteins, LDL/metabolism , Scavenger Receptors, Class A/physiology , Amino Acid Motifs , Amino Acid Sequence , Animals , CHO Cells , Cell Membrane/metabolism , Clathrin/metabolism , Coated Pits, Cell-Membrane/metabolism , Cricetinae , Cricetulus , Cytoplasm , Ligands , Molecular Sequence Data , Mutation , Protein Structure, Tertiary , Scavenger Receptors, Class A/genetics , Transfection
12.
Biochem Biophys Res Commun ; 343(2): 470-4, 2006 May 05.
Article in English | MEDLINE | ID: mdl-16546122

ABSTRACT

Ultrasound-targeted microbubble destruction had been employed in gene delivery and promised great potential. Liver has unique features that make it attractive for gene therapy. However, it poses formidable obstacles to hepatocyte-specific gene delivery. This study was designed to test the efficiency of therapeutic gene transfer and expression mediated by ultrasound/microbubble strategy in HepG2 cell line. Air-filled albumin microbubbles were prepared and mixed with plasmid DNA encoding low density lipoprotein receptor (LDLR) and green fluorescent protein. The mixture of the DNA and microbubbles was administer to cultured HepG2 cells under variable ultrasound conditions. Transfection rate of the transferred gene and cell viability were assessed by FACS analysis, confocal laser scanning microscopy, Western blot analysis and Trypan blue staining. The result demonstrated that microbubbles with ultrasound irradiation can significantly elevate exogenous LDLR gene expression and the expressed LDLRs were functional and active to uptake their ligands. We conclude that ultrasound-targeted microbubble destruction has the potential to promote safe and efficient LDLR gene transfer into hepatocytes. With further refinement, it may represent an effective nonviral avenue of gene therapy for liver-involved genetic diseases.


Subject(s)
DNA/administration & dosage , Gene Targeting/methods , Hepatoblastoma/genetics , Hepatoblastoma/metabolism , Receptors, LDL/metabolism , Sonication , Transfection/methods , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Humans , Liver Neoplasms/genetics , Liver Neoplasms/metabolism , Receptors, LDL/genetics
13.
Atherosclerosis ; 185(2): 433-7, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16046221

ABSTRACT

Elevation in plasma triglycerides (TG) has been widely accepted as a coronary artery disease (CAD) risk predictor. Recently, a new apolipoprotein playing an important role in TG metabolism named apolipoprotein AV (apoAV) was discovered, which is encoded by the APOA5 gene. Several single nucleotide polymorphisms (SNPs) of APOA5 associated with increased TG concentrations have been identified. We here report that a recently identified genetic variant, c.553G>T in the APOA5 gene which causes a substitution of a cysteine for a glycine residue at amino acid residue 185(G185C) is also associated with increased TG levels. To investigate the association between this genetic variation and the risk of CAD, a case-control study comprising 232 patients with CAD and 302 controls from the same area of China was performed. The minor allele frequencies of c.553G > T for the CAD and control groups were 7.76 and 3.97%, respectively (P = 0.008). In both the CAD and control groups, the T allele carriers had higher serum TG levels than homozygous carriers of the major G allele (CAD group: 2.67 +/- 1.48 mmol/l versus 1.95 +/- 1.02 mmol/l, P = 0.021; controls: 2.31 +/- 1.20 mmol/l versus 1.68 +/- 0.95 mmol/l, P = 0.002). After adjustment for age, gender, body mass index, smoking status, glucose and presence of hypertension, the odds ratio (OR) for CAD in the T allele carriers was 2.089 (95% CI = 1.140-3.830, P = 0.017), in comparison to the individuals without the T allele. These results suggest that the APOA5 c.553G > T polymorphism is an important predictor for hypertriglyceridemia and CAD.


Subject(s)
Apolipoproteins/genetics , Coronary Artery Disease/genetics , Triglycerides/blood , Amino Acid Substitution , Apolipoprotein A-V , Apolipoproteins A , Case-Control Studies , Coronary Artery Disease/blood , Female , Gene Frequency , Genetic Predisposition to Disease , Genetic Variation , Genotype , Humans , Lipids/blood , Male , Middle Aged , Polymorphism, Genetic
14.
Atherosclerosis ; 188(1): 84-94, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16300769

ABSTRACT

Low-density lipoprotein (LDL) inhibits endothelium-dependent vasorelaxation. The aim of this study was to determine whether pyridoxine supplementation improves indices of LDL-induced endothelial dysfunction. Human umbilical vein endothelial cells (HUVEC) were incubated with native LDL (nLDL) from healthy subjects, oxidized LDL (oxLDL, formed by nLDL oxidation) or nLDL from type II diabetic patients (dLDL), in the absence or presence of pyridoxine; nitric oxide synthase (NOS) activity, cyclic GMP and expression of NOS isoforms were measured, as well as thiobarbituric acid reactive substances (TBARS) in HUVEC supernatants and amino acid concentrations in HUVEC lysates. All LDL species inhibited total NOS activity, whilst increasing the much smaller Ca2+-independent component of NOS activity, the effects of oxLDL being greatest and those of nLDL smallest; in accordance with these findings, NOS type 3 expression decreased and NOS type 2 expression increased, with a resultant decrease in bioactive nitric oxide (NO), in HUVEC treated with each LDL species, with the same rank order of potency. LDL species also increased TBARS in HUVEC supernatants as well as homocysteine concentrations in HUVEC lysates, nLDL < dLDL < oxLDL. Pyridoxine largely prevented all LDL-induced changes in NOS activity and isoform expression, as well as in TBARS and homocysteine. The findings suggest that pyridoxine prevents LDL-induced dysfunction of endothelial cell NO generation, most likely through its antioxidant effects as well as through its effects on cellular homocysteine metabolism. This has important potential therapeutic implications for cardiovascular disease prevention.


Subject(s)
Endothelial Cells/drug effects , Endothelium, Vascular/drug effects , Lipoproteins, LDL/antagonists & inhibitors , Nitric Oxide/biosynthesis , Pyridoxine/pharmacology , Vitamin B Complex/pharmacology , Cyclic GMP/analysis , Cyclic GMP/metabolism , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Female , Humans , Lipoproteins, LDL/pharmacology , Male , Middle Aged , Nitric Oxide/antagonists & inhibitors , Nitric Oxide Synthase Type II/drug effects , Nitric Oxide Synthase Type III/antagonists & inhibitors , Oxidative Stress/drug effects , Thiobarbituric Acid Reactive Substances/analysis , Thiobarbituric Acid Reactive Substances/metabolism , Umbilical Cord/cytology
15.
J Nanosci Nanotechnol ; 5(8): 1273-6, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16193991

ABSTRACT

We report here testosterone deficiency in diet-induced hypercholesterolemic mice. We attempted to compare the liver protein profiles between hypercholesterolemic and normal mice by using the technology of proteomics. Protein extractions from mice livers were separated by two-dimensional electrophoresis and the gels were analysed with image analysis software 2D Elite 4.0. The differentially expressed proteins were identified primarily by comparing with reference gel images in the SWISS 2DPAGE database and then confirmed by peptide mass fingerprinting. Sixteen differentially expressed protein spots (>2-fold) were detected and 8 of which were identified as major urinary proteins, carbonic anhydrase III, and glutathione S-transferase P2, which are known to be regulated by androgens. The expression of these three proteins was statistically lower in the livers of hypercholesterolemic mice. Meanwhile, the testosterone levels in serum, testis, and liver were lower in hypercholesterolemic mice than those in normal mice, when human chorionic gonadotrophin was injected intramuscularly. These results suggest a testosterone deficiency in diet-induced hypercholesterolemic mice.


Subject(s)
Hypercholesterolemia/metabolism , Liver/metabolism , Protein Array Analysis , Testosterone/metabolism , Animals , Diet, Atherogenic , Electrophoresis, Gel, Two-Dimensional , Hypercholesterolemia/etiology , Male , Mass Spectrometry , Mice , Mice, Inbred C57BL , Nanotechnology , Proteins/isolation & purification , Proteins/metabolism , Proteomics
16.
Zhonghua Xin Xue Guan Bing Za Zhi ; 33(7): 627-30, 2005 Jul.
Article in Chinese | MEDLINE | ID: mdl-16080812

ABSTRACT

OBJECTIVE: To investigate the association of R219K and M883I polymorphisms of ATP binding cassette transporter 1 gene with lipid metabolism and the susceptibility to coronary atherosclerotic heart disease in Chinese population. METHODS: Genotypes were determined by PCR-restriction fragment length polymorphism and Primer introduced restriction analysis-PCR techniques, respectively, in 248 unrelated CHD-free controls and 224 CHD cases. RESULTS: Smoking, high blood pressure and high serum glucose were independent risk factors for CHD. Multivariate logistic regression analysis revealed that individuals carrying at least one 219K variant allele (RK + KK genotypes) had a significantly decreased risk for CHD (adjusted OR = 0.41; 95% CI = 0.27-0.61) compared with the wild-type genotype (219RR) and only 883II homozygotes displayed a decreased risk for CHD (adjusted OR = 0.54; 95% CI = 0.26-1.11) compared with 883MM and 883MI genotypes. Furthermore, compared with individuals with both wild genotypes (219 RR and 883 MM or 883 MI) other individuals with all other assembly genotypes had a significantly decreased risk (adjusted OR = 0.39, 95% CI = 0.26-0.60). Plasma HDL-C in 219K allele carriers were markedly higher than those in 219 K non-carriers in controls (P = 0.037). CONCLUSION: The ABCA1 R219K polymorphism may be involved in the variability of serum HDL-C and the susceptibility to coronary artery disease.


Subject(s)
ATP-Binding Cassette Transporters/genetics , Coronary Artery Disease/genetics , Genetic Predisposition to Disease , ATP Binding Cassette Transporter 1 , Aged , Case-Control Studies , Female , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide
17.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi ; 22(3): 281-3, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15952115

ABSTRACT

OBJECTIVE: To investigate the relationship between apolipoprotein A5(apoA5) - 1131T > C polymorphism and the susceptibility of coronary artery disease (CAD) in Chinese. METHODS: The restriction fragment length polymorphism of apoA5 gene - 1131T > C was studied using PCR in a case-control study which enrolled 235 patients with CAD diagnosed by angiography and 262 healthy controls from Jiangsu province. RESULTS: The frequencies of T, C allele were 59.57%ì40.43% and 65.65%, 34.35% in CAD group and control group respectively. There was statistically significant difference in allele frequencies between CAD group and control group (P < 0.05). The susceptibility to CAD for the CC genotype was much higher than that for wild type TT (OR = 1.872, 95% CI = 1.039 - 3.376, P = 0.037), even after the use of Logistic regression models (OR = 2.285, 95% CI = 1.222 - 4.274, P = 0.012). In control group, there was significant difference in TG levels among different genotypes, the C allele carriers had higher serum TG concentration (P = 0.007). CONCLUSION: apoA5 - 1131T > C polymorphism is associated with an increased risk of CAD and is also in strong association with serum TG levels.


Subject(s)
Apolipoproteins A/genetics , Coronary Artery Disease/genetics , Polymorphism, Single Nucleotide/genetics , Aged , Apolipoprotein A-V , Asian People/genetics , China , Coronary Artery Disease/blood , Female , Gene Frequency , Genetic Predisposition to Disease/genetics , Humans , Lipids/blood , Logistic Models , Male , Middle Aged , Triglycerides/blood
18.
Biochem J ; 390(Pt 2): 447-53, 2005 Sep 01.
Article in English | MEDLINE | ID: mdl-15836436

ABSTRACT

It is known that glycine protects mammalian cells against ischaemic cell injury by preventing cellular membrane leakage. However, the molecular mechanisms have not yet been clearly elucidated. The purpose of the present study was to clarify whether GlyR (glycine receptor) acts as a key mediator in cytoprotection of glycine. cDNA encoding human GlyRa1 (a1-subunit of glycine receptor) was transfected into HEK-293 cells. The membrane integrity of the cells with or without GlyRa1 was examined by the uptake of marker compounds, the release of LDH (lactate dehydrogenase) and the exclusion of Trypan Blue. Glycine prevented the permeability of 70 kDa dextrans and 140 kDa LDH in the cells in which GlyR was expressed under conditions of ATP depletion. The inhibition of endogenous GlyR expression by RNA interference attenuated the cytoprotection by glycine. Furthermore, the mutation of Tyr202 to phenylalanine in GlyRa1 blocked the glycine-mediated cytoprotection, while the mutation of Tyr202 to leucine abolished the cytoprotection by strychnine. Our results suggested that the cytoprotection of glycine against ATP-depletion-induced injury might be mediated by GlyR.


Subject(s)
Adenosine Triphosphate/metabolism , Cytoprotection/drug effects , Glycine/pharmacology , Kidney/cytology , Kidney/drug effects , Receptors, Glycine/metabolism , Animals , Cell Line , Cell Membrane Permeability , Glycine/metabolism , Humans , Kidney/metabolism , L-Lactate Dehydrogenase/metabolism , Mutation , RNA Interference , Receptors, Glycine/genetics , Transfection
19.
Acta Biochim Biophys Sin (Shanghai) ; 36(12): 824-31, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15592650

ABSTRACT

Although viral vectors are efficient systems to transfer foreign genes into cells or target tissues, safety issues remain in relation to human gene therapy. Microbubbles currently used as ultrasound contrast agents have been applied in transfection of genes. This study was designed to test the transfection efficiency and the expression of exogenous gene mediated by ultrasound irradiation enhanced air filled albumin microbubbles in ECV304 cell line in vitro and the heart of the mouse in vivo. Air filled microbubbles (2.0-4.0 microm in diameter) were created by sonicating the mixture of human albumin, glucose, mannitol and special additive that was designed for stabilization. Plasmid DNA loading the reporter genes was gently mixed with microbubbles. The mixture of plasmid DNA and microbubbles was administrated to cultured ECV304 cells and BALB/c mice (tail vein injection) under different ultrasound/microbubble conditions, and then the transfection and expression efficiency were examined. The results both in vivo and in vitro demonstrated that microbubble with ultrasound irradiation could significantly elevate the exogenous gene expression as compared with microbubble or ultrasound only. Overall, the present study showed that the ultrasound-target microbubble destruction method enhanced the exogenous gene expression in vivo and in vitro, and provided a gene therapy way not only efficient but also easy to be manipulated and carried out in clinical.


Subject(s)
Microbubbles , Myocardium/metabolism , Transfection/methods , Ultrasonics , Animals , Cells, Cultured , Endothelium, Vascular/cytology , Green Fluorescent Proteins/biosynthesis , Green Fluorescent Proteins/genetics , Humans , Luciferases/biosynthesis , Luciferases/genetics , Male , Mice , Mice, Inbred BALB C , Microscopy, Confocal , Plasmids/genetics , Umbilical Veins/cytology , beta-Galactosidase/biosynthesis , beta-Galactosidase/genetics
20.
Zhonghua Yi Xue Za Zhi ; 84(17): 1470-4, 2004 Sep 02.
Article in Chinese | MEDLINE | ID: mdl-15500748

ABSTRACT

OBJECTIVE: Renal cell hypertrophy is an important compensatory mechanism of chronic renal diseases, which has been shown closely correlated with the activation of intrarenal renin angiotensin system. However, the exact mechanism is still uncertain. The present study was to investigate the role of connective tissue growth factor (CTGF) in mediating the effect of angiotensin (AngII) induced human proximal tubular cell (HK-2) hypertrophy. METHODS: The cell line, HK-2, was grown in Dulbeccos's Modified Eagle's Medium (DMEM) containing 10% heat inactivated fetal calf serum (FCS). After rested in serum-free medium for 24 hours, The influence of anti-CTGF antibody on AngII induced cell protein de novo synthesis and total protein content were determined by [(3)H]-leucine incorporation and Coomassie brilliant blue G250 technique respectively. Fluorescence-activated cell sorter (FACS) flow cytometer was used to analyze the effect of anti-CTGF antibody on cell cycle distribution. The change of cellular size was determined by scanning electronic microscope (SEM). RESULTS: AngII significantly induced the increase of [(3)H] leucine incorporation in dose [AngII (mol/L): 0: 6926 +/- 1034; 10(-9): 8455 +/- 2137; 10(-7): 10 741 +/- 802; 10(-5): 12 945 +/- 1377] and time [AngII (10(-7)mol/L): 0 h: 5584 +/- 1016; 24 h: 7379 +/- 957; 48 h: 10 741 +/- 802; 72 h: 16 606 +/- 1177] dependent manner. Meanwhile, the influence of AngII on cell total protein content showed the similar manner. Anti-CTGF antibody significantly inhibited the AngII induced above effects dose and time dependently. 48 h after the stimulation by AngII (10(-7)mol/L), the percentage of cells in G0-G1 phase (76.09% +/- 1.82%) and the average cell diameter (20.6 microm +/- 3.8 microm) was significantly increased compared to the control (62.1% +/- 2.5%, 11.9 microm +/- 1.6 microm, P < 0.01 respectively), which could markedly reversed by treatment with anti-CTGF antibody (71.68% +/- 1.78%; 16.4 microm +/- 3.2 microm, P < 0.05, 0.01 respectively vs AngII group). CONCLUSION: AngII could induce the development of tubular cell hypertrophy, which might be mediated by CTGF.


Subject(s)
Angiotensin II/pharmacology , Immediate-Early Proteins/physiology , Intercellular Signaling Peptides and Proteins/physiology , Kidney Tubules, Proximal/pathology , Cell Line , Connective Tissue Growth Factor , Endothelial Cells/cytology , Humans , Hypertrophy , Kidney Tubules, Proximal/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...